Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies.

Novelli L, Chimenti MS, Chiricozzi A, Perricone R.

Autoimmun Rev. 2014 Jan;13(1):64-9. doi: 10.1016/j.autrev.2013.08.006. Epub 2013 Sep 8. Review.

PMID:
24021172
2.

Role of IL-17 in psoriasis and psoriatic arthritis.

Raychaudhuri SP.

Clin Rev Allergy Immunol. 2013 Apr;44(2):183-93. doi: 10.1007/s12016-012-8307-1. Review.

PMID:
22362575
3.

IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.

Mitra A, Raychaudhuri SK, Raychaudhuri SP.

Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:21-33. doi: 10.1016/S0001-7310(14)70015-8. Review.

PMID:
25398489
4.

Scid mouse model of psoriasis: a unique tool for drug development of autoreactive T-cell and th-17 cell-mediated autoimmune diseases.

Raychaudhuri SK, Raychaudhuri SP.

Indian J Dermatol. 2010 Apr-Jun;55(2):157-60. doi: 10.4103/0019-5154.62752.

5.

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis.

Durham LE, Kirkham BW, Taams LS.

Curr Rheumatol Rep. 2015 Aug;17(8):55. doi: 10.1007/s11926-015-0529-9. Review.

PMID:
26209291
6.

Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.

Sakkas LI, Bogdanos DP.

Autoimmun Rev. 2017 Jan;16(1):10-15. doi: 10.1016/j.autrev.2016.09.015. Epub 2016 Sep 22. Review.

PMID:
27666819
7.

Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.

Raychaudhuri SK, Saxena A, Raychaudhuri SP.

Clin Rheumatol. 2015 Jun;34(6):1019-23. doi: 10.1007/s10067-015-2961-7. Epub 2015 May 5. Review.

PMID:
25939522
8.

Targeting the IL-23/IL-17 axis for the treatment of psoriasis and psoriatic arthritis.

Alunno A, Carubbi F, Cafaro G, Pucci G, Battista F, Bartoloni E, Giacomelli R, Schillaci G, Gerli R.

Expert Opin Biol Ther. 2015;15(12):1727-37. doi: 10.1517/14712598.2015.1084284. Epub 2015 Sep 7. Review.

PMID:
26653110
9.

Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis.

Mease PJ.

Curr Opin Rheumatol. 2015 Mar;27(2):127-33. doi: 10.1097/BOR.0000000000000147. Review.

PMID:
25599143
10.

The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment.

Frleta M, Siebert S, McInnes IB.

Curr Rheumatol Rep. 2014 Apr;16(4):414. doi: 10.1007/s11926-014-0414-y. Review.

PMID:
24570394
11.

Interleukin 17A: toward a new understanding of psoriasis pathogenesis.

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S.

J Am Acad Dermatol. 2014 Jul;71(1):141-50. doi: 10.1016/j.jaad.2013.12.036. Epub 2014 Mar 18. Review.

PMID:
24655820
12.

The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.

Toussirot E.

Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68. Review.

PMID:
22280236
13.

Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.

Kirkham BW, Kavanaugh A, Reich K.

Immunology. 2014 Feb;141(2):133-42. doi: 10.1111/imm.12142. Review.

14.

Bone remodeling in psoriasis and psoriatic arthritis: an update.

Paine A, Ritchlin C.

Curr Opin Rheumatol. 2016 Jan;28(1):66-75. doi: 10.1097/BOR.0000000000000232. Review.

PMID:
26555451
15.

T cell responses in psoriasis and psoriatic arthritis.

Diani M, Altomare G, Reali E.

Autoimmun Rev. 2015 Apr;14(4):286-92. doi: 10.1016/j.autrev.2014.11.012. Epub 2014 Nov 28. Review.

PMID:
25445403
16.

Prospective new biologic therapies for psoriasis and psoriatic arthritis.

Mortel MR, Emer J.

J Drugs Dermatol. 2010 Aug;9(8):947-58. Review.

PMID:
20684145
17.

Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.

Channual J, Wu JJ, Dann FJ.

Dermatol Ther. 2009 Jan-Feb;22(1):61-73. doi: 10.1111/j.1529-8019.2008.01217.x. Review.

PMID:
19222518
18.

The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis.

Makredes M, Robinson D Jr, Bala M, Kimball AB.

J Am Acad Dermatol. 2009 Sep;61(3):405-10. doi: 10.1016/j.jaad.2009.02.015.

PMID:
19700012
19.

Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.

Johnsson HJ, McInnes IB.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S115-8. Epub 2015 Oct 15. Review.

PMID:
26471946
20.

Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.

Kivelevitch DN, Menter A.

Immunotherapy. 2015;7(4):323-33. doi: 10.2217/imt.14.113. Review.

PMID:
25917624

Supplemental Content

Support Center